Cyclophosphamide in systemic sclerosis: still in search of a 'real life' scenario

In systemic sclerosis (SSc), there is no proven treatment to prevent disease progression. In a recent meta-analysis of three randomised controlled trials (RCTs) and six open prospective studies on cyclophosphamide (CYC), no significant changes in lung function were observed. However, CYC is associat...

Descripción completa

Detalles Bibliográficos
Autores principales: Miniati, Irene, Valentini, Gabriele, Cerinic, Marco Matucci
Formato: Texto
Lenguaje:English
Publicado: BioMed Central 2009
Materias:
Editorial
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2688227/
https://www.ncbi.nlm.nih.gov/pubmed/19226435
http://dx.doi.org/10.1186/ar2576
Descripción
Sumario:In systemic sclerosis (SSc), there is no proven treatment to prevent disease progression. In a recent meta-analysis of three randomised controlled trials (RCTs) and six open prospective studies on cyclophosphamide (CYC), no significant changes in lung function were observed. However, CYC is associated with an improvement of Mahler's dyspnea index, short form-36 (physical and mental domains), and health-related quality of life, contributing to the amelioration of patients' functional status. Further RCTs on early SSc are needed to assess the real efficacy of CYC in inducing remission and increasing survival.

Ejemplares similares